Wednesday, November 5, 2014

Promise and Peril: The New Hep C Drugs

Promise and Peril: The New Hep C Drugs

By Liz Highleyman
From AIDS Community Research Initiative of America
November 4, 2014

In the Pipeline
A 12-week regimen of AbbVie's "3D" combo pill (the protease inhibitor ABT-450, NS5A inhibitor ombitasvir, and polymerase inhibitor dasabuvir) has also demonstrated high cure rates. In the PEARL-III trial, SVR rates reached 99% for previously untreated genotype 1 patients without liver cirrhosis. AbbVie expects approval by the end of 2014. 
Similarly, a regimen of daclatasvir, asunaprevir, and the polymerase inhibitor BMS-791325 taken for 12 weeks cured 92% of previously untreated patients. Merck also has a promising combo in the works: the protease inhibitor MK-5172 and NS5A inhibitor MK-8742. 
Continue reading @ The Body 

No comments:

Post a Comment